Topical tacrolimus achieves clinical remission but only marginally delays onset of advanced therapy in chronic proctitis: a dual center retrospective cohort study

Background Topical tacrolimus (TT) is an off-label treatment for chronic refractory proctitis and may represent an alternative to advanced therapies, which can be limited by costs, systemic adverse effects, and patient preferences. However, evidence regarding its ability to delay escalation to advanced therapies is limited.Methods We conducted a retrospective cohort study at two Danish IBD centers and included all patients with ulcerative proctitis treated with TT between 2022 and 2025. Treatment efficacy was assessed by bowel movements and rectal bleeding before and after treatment. Remission was defined as <3 bowel movements all without blood.Results Thirteen patients were included, receiving 17 courses of TT (duration 8 weeks) with a median follow-up of 644 days (IQR 447–779). Clinical remission at the end of treatment was achieved in 9 (53%) courses. Bowel movements decreased significantly in patients attaining remission (from 6 to 1 vs. 6 to 6, p = 0.01), as did the proportion of patients reporting rectal bleeding (78% to 0% vs. 75% to 50%, p = 0.009) and fecal calprotectin (465 mg/kg to 74 vs. 295 mg/kg to 1,470, p = 0.03). Mild adverse events were reported in 4 patients. Time to escalation to advanced therapy was median 31 days for patients attaining remission (IQR 0–174) vs. 0 (0–0) for non-remission (p = 0.03). Only 2 (22%) TT ending in remission were not escalated to advanced therapies.Conclusion TT demonstrated short-term clinical efficacy and favorable safety in refractory chronic proctitis but only marginally delayed escalation to advanced therapies thus suggesting its role as a localized bridge to systemic therapies.

Authors

Institutions

Publication Details

Journal
Scandinavian Journal of Gastroenterology
Published
2026-11-21
DOI
https://doi.org/10.1080/00365521.2026.2766470
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Topical tacrolimus achieves clinical remission but only marginally delays onset of advanced therapy in chronic proctitis: a dual center retrospective cohort study

Ruben Due Lorentsen, Casper Steenholdt, Anmar Al-Kabban
Scandinavian Journal of Gastroenterology
Inflammatory Bowel Disease
article

Topical tacrolimus achieves clinical remission but only marginally delays onset of advanced therapy in chronic proctitis: a dual center retrospective cohort study

Ruben Due Lorentsen, Casper Steenholdt, Anmar Al-Kabban
article en

Abstract

Background Topical tacrolimus (TT) is an off-label treatment for chronic refractory proctitis and may represent an alternative to advanced therapies, which can be limited by costs, systemic adverse effects, and patient preferences. However, evidence regarding its ability to delay escalation to advanced therapies is limited.Methods We conducted a retrospective cohort study at two Danish IBD centers and included all patients with ulcerative proctitis treated with TT between 2022 and 2025. Treatment efficacy was assessed by bowel movements and rectal bleeding before and after treatment. Remission was defined as <3 bowel movements all without blood.Results Thirteen patients were included, receiving 17 courses of TT (duration 8 weeks) with a median follow-up of 644 days (IQR 447–779). Clinical remission at the end of treatment was achieved in 9 (53%) courses. Bowel movements decreased significantly in patients attaining remission (from 6 to 1 vs. 6 to 6, p = 0.01), as did the proportion of patients reporting rectal bleeding (78% to 0% vs. 75% to 50%, p = 0.009) and fecal calprotectin (465 mg/kg to 74 vs. 295 mg/kg to 1,470, p = 0.03). Mild adverse events were reported in 4 patients. Time to escalation to advanced therapy was median 31 days for patients attaining remission (IQR 0–174) vs. 0 (0–0) for non-remission (p = 0.03). Only 2 (22%) TT ending in remission were not escalated to advanced therapies.Conclusion TT demonstrated short-term clinical efficacy and favorable safety in refractory chronic proctitis but only marginally delayed escalation to advanced therapies thus suggesting its role as a localized bridge to systemic therapies.

Scandinavian Journal of Gastroenterology
University of Southern Denmark (DK), Odense University Hospital (DK), Zealand University Hospital (DK)
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon